These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7829583)

  • 1. Prospects for application of biotechnology-derived biomaterials.
    Hellman KB; Picciolo GL; Fox CF
    J Cell Biochem; 1994 Oct; 56(2):210-24. PubMed ID: 7829583
    [No Abstract]   [Full Text] [Related]  

  • 2. Introductory remarks to the biotechnology applications in biomaterials workshop.
    Burlington DB
    J Cell Biochem; 1994 Oct; 56(2):145-6. PubMed ID: 7829570
    [No Abstract]   [Full Text] [Related]  

  • 3. Bringing safe and effective cell therapies to the bedside.
    Preti RA
    Nat Biotechnol; 2005 Jul; 23(7):801-4. PubMed ID: 16003360
    [No Abstract]   [Full Text] [Related]  

  • 4. Overview of FDA regulation of human cellular and tissue-based products.
    Wells MA
    Food Drug Law J; 1997; 52(4):401-8. PubMed ID: 10346672
    [No Abstract]   [Full Text] [Related]  

  • 5. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood products part of FDA xenotransplant plan.
    Fox JL
    Nat Biotechnol; 2000 Mar; 18(3):258. PubMed ID: 10700130
    [No Abstract]   [Full Text] [Related]  

  • 7. Applied biomaterials standards report.
    Daniels AU
    J Biomed Mater Res; 1987 Dec; 21(A3 Suppl):247-50. PubMed ID: 3429464
    [No Abstract]   [Full Text] [Related]  

  • 8. Regenerative medicine.
    Petit-Zeman S
    Nat Biotechnol; 2001 Mar; 19(3):201-6. PubMed ID: 11231542
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA transgenic animal guidance finally surfaces.
    Fox JL
    Nat Biotechnol; 2008 Nov; 26(11):1205-7. PubMed ID: 18997745
    [No Abstract]   [Full Text] [Related]  

  • 10. Understanding external controls over the commercial introduction of engineered human tissues. Assessing regulatory and liability issues.
    Smith DS
    Clin Plast Surg; 1999 Oct; 26(4):537-48, vii. PubMed ID: 10553211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biomaterials and public health: avoid the drift].
    Muster D; Le Borgne E
    Rev Stomatol Chir Maxillofac; 1997 Nov; 98 Suppl 1():50-5. PubMed ID: 9471697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compliance with Good Manufacturing Practices for facilities engaged in vector production, cell isolation, and genetic manipulations.
    Steel MP; Roessler BJ
    Curr Opin Biotechnol; 1999 Jun; 10(3):295-7. PubMed ID: 10361080
    [No Abstract]   [Full Text] [Related]  

  • 13. Simplifying the extracellular matrix for 3-D cell culture and tissue engineering: a pragmatic approach.
    Prestwich GD
    J Cell Biochem; 2007 Aug; 101(6):1370-83. PubMed ID: 17492655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomaterials applicability: establishing suitable "materials' equivalency" protocols.
    Baier RE
    J Appl Biomater; 1994; 5(4):377-8. PubMed ID: 8580547
    [No Abstract]   [Full Text] [Related]  

  • 15. The law of biotechnology: a mystery inside an enigma.
    Brown SA
    Healthspan; 1988 May; 5(5):7-11. PubMed ID: 10288655
    [No Abstract]   [Full Text] [Related]  

  • 16. The ability of current biologics law to accommodate emerging technologies.
    Carter MJ
    Food Drug Law J; 1996; 51(3):375-80. PubMed ID: 11797714
    [No Abstract]   [Full Text] [Related]  

  • 17. What is the greatest regulatory challenge in the translation of biomaterials to the clinic?
    Prestwich GD; Bhatia S; Breuer CK; Dahl SL; Mason C; McFarland R; McQuillan DJ; Sackner-Bernstein J; Schox J; Tente WE; Trounson A
    Sci Transl Med; 2012 Nov; 4(160):160cm14. PubMed ID: 23152323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASTM lights the way for tissue engineered medical products standards: jump start for combination medical products that restore biological function of human tissues.
    Picciolo GL; Stocum DL
    Stand News; 2001 Jan; 29(1):30-5. PubMed ID: 11833591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. US animal biotech regulations "may not be adequate".
    Fox JL
    Nat Biotechnol; 2002 Oct; 20(10):959. PubMed ID: 12355099
    [No Abstract]   [Full Text] [Related]  

  • 20. What are biologics? A comparative legislative, regulatory and scientific analysis.
    Korwek EL
    Food Drug Law J; 2007; 62(2):257-304. PubMed ID: 17632962
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.